Global Epigenetics Market Worth $8 Billion by 2017
DALLAS, January 15, 2013 /PRNewswire/ --
The report "Epigenetics Market (Epigenomics, DNA Methylation, Histone Modifications, RNA interference, Cancer Therapeutics, Personalized Medicine) (2012 - 2017)" analyses the global epigenetics market by region, applications and epigenetic mechanisms with five year revenue forecasts. It also identifies the factors driving and restraining the global epigenetics market with analysis of trends, opportunities and challenges.
The market is segmented and the revenue is forecasted on the basis of major regions such as America, Europe, Asia and Rest of the World (ROW) covering the key countries for each region. Further, the market is also segmented and revenues are forecasted on the basis of applications and disease indications.
Browse 19 market data tables with 16 figures spread through 156 slides and in-depth TOC on "Epigenetics Market (Epigenomics, DNA Methylation, Histone Modifications, RNA interference, Cancer Therapeutics, Personalized Medicine) (2012 - 2017)".
Early buyers will receive 10% customization on reports.
In the post genomic era, epigenetics is gaining importance as a promising scientific approach for understanding the influence of the epigenetic mechanisms in cancer and various other diseases. Rapid advancements have been occurring specifically in the field of cancer therapeutics.
The market for epigenetics screening tools such as enzymes, Chip kits, assays for analyzing various epigenetic mechanisms are increasing at a higher rate due to increased utilization in the research field. There has been a significant growth in biotechnology industry based on the revenues from epigenetic tools. The pharmaceutical industry also experienced a considerable growth based on sales revenues of the four epigenetic drugs, for example around $1 Billion in the year 2011 and is expected to have an increased growth rate in the coming years.
Strong academic research, high demand for treatment of cancer and non-oncology conditions, rapid screening tools are some of the factors driving the epigenetics market. Therapeutic applications in non-oncology indications such as inflammatory diseases, autoimmune diseases, neurodegenerative disorders and personalized medicine are some high growth and emerging areas that are expected to drive the global market of epigenetics in coming years. The global market for epigenetics in terms of revenue is estimated to be worth $2.6 Billion in 2012 and is expected to reach $8 Billion by 2017, growing at a CAGR of 25% from 2012 to 2017.
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.
MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. M&M covers thirteen industry verticals, including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals [ http://www.marketsandmarkets.com/pharmaceutical-market-research-3.html ], semiconductor and electronics, and telecommunications and IT.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. To know more about us and our reports, please visit our website http://www.marketsandmarkets.com
North - Dominion Plaza
17304 Preston Road
Suite 800, Dallas, TX 75252
MarketsandMarkets Blog @ http://www.marketsandmarketsblog.com
Mer från detta företag
Cell Expansion Market Worth $14.8 Billion by 2019
29 Oct, 2014, 18:30 CET
Skapa innehåll för din webbplats
Förbättra din webbplats eller blogg med PR Newswires skräddarsydda nyhetsflöden.
Kontakta PR Newswire
Skicka oss ett mail till email@example.com eller ring oss på +46 (0)8 1200 1300
Bli en PR Newswire kund
Begär mer information , se PR Newswire produkter & tjänster eller ring oss på +46 (0)8 1200 1300